Core Viewpoint - The company is focusing on developing a large model application primarily for cardiovascular diseases, which includes risk assessment capabilities and has shown positive results in preliminary trials [1] Group 1 - The company has launched a new smart ring product that features atrial fibrillation monitoring and aims to cover more health monitoring projects [1] - The company is currently unable to predict the impact of these new business developments on future performance [1]

截至2026年1月19日收盘，乐心医疗(300562)报收于15.15元，下跌0.98%，换手率7.5%，成交量12.17万 手，成交额1.85亿元。 当日关注点 1月19日主力资金净流出630.43万元；游资资金净流入696.36万元；散户资金净流出65.93万元。 来自交易信息汇总：1月19日主力资金净流出630.43万元，游资资金净流入696.36万元。 来自公司公告汇总：乐心医疗获II类医疗器械注册证，其血糖仪产品GBZ41-B支持蓝牙数据上传 功能。 公司公告汇总关于获得医疗器械注册证的公告 广东乐心医疗电子股份有限公司近日收到广东省药品监督管理局通知，其申报的血糖仪产品已获II类医 疗器械注册证，注册证编号为粤械注准20262220067，型号为GBZ41-B和GBZ41。该产品基于电化学原 理，配合血糖试纸用于定量检测全血葡萄糖浓度，适用于家庭患者及医疗机构专业人员使用。其中 GBZ41-B型号具备蓝牙功能，可将数据上传至指定APP。本次注册证的取得是公司募投项目的重要进 展，有助于提升产品竞争力，拓展血糖业务，推动战略落地。产品实际销售情况受市场推广影响，未来 业绩影响尚不确定。 以上内容为证 ...

Core Viewpoint - 乐心医疗 has received II class medical device registration for its blood glucose meter, which is expected to enhance its product competitiveness and expand its blood glucose business [1] Group 1: Company Performance - As of January 19, 2026, 乐心医疗's stock closed at 15.15 yuan, down 0.98% from the previous trading day, with a total market capitalization of 3.312 billion yuan [1] - The stock opened at 15.19 yuan, reached a high of 15.4 yuan, and a low of 14.95 yuan, with a trading volume of 185 million yuan and a turnover rate of 7.5% [1] Group 2: Product Development - The blood glucose meter, based on electrochemical principles, is designed for quantitative detection of whole blood glucose levels, suitable for home patients and healthcare professionals [1] - The model GBZ41-B features Bluetooth functionality, allowing data to be uploaded to a designated app [1] - The acquisition of the registration certificate is a significant advancement for the company's fundraising project, aiding in the implementation of its strategy [1] Group 3: Market Impact - The actual sales performance of the product will be influenced by market promotion efforts, and the future impact on the company's performance remains uncertain [1]

格隆汇1月19日丨乐心医疗(300562.SZ)公布，近日收到广东省药品监督管理局的通知，获悉公司申报的 血糖仪医疗器械注册事宜已通过审批，上述产品由主机和配件组成，该产品基于电化学原理，与配套血 糖试纸共同使用。用于家庭患者定量检测指尖新鲜毛细血管全血和医院专业人士定量检测静脉全血中的 葡萄糖浓度。本产品仅供成人体外监测使用。供医疗机构中专业人员专业检测以及熟练掌握该项操作的 患有糖尿病的非专业人员或其家属操作。血糖仪只用于监测糖尿病人血糖控制的效果，而不能用于糖尿 病的诊断和筛查，也不能作为治疗药物调整的依据。其中型号为"GBZ41-B"的血糖仪具备蓝牙功能，可 将测量结果上传至指定APP，方便用户及时查看个人及家人的健康情况。 ...

格隆汇1月19日丨乐心医疗(300562.SZ)公布，近日收到广东省药品监督管理局的通知，获悉公司申报的 血糖仪医疗器械注册事宜已通过审批，上述产品由主机和配件组成，该产品基于电化学原理，与配套血 糖试纸共同使用。用于家庭患者定量检测指尖新鲜毛细血管全血和医院专业人士定量检测静脉全血中的 葡萄糖浓度。本产品仅供成人体外监测使用。供医疗机构中专业人员专业检测以及熟练掌握该项操作的 患有糖尿病的非专业人员或其家属操作。血糖仪只用于监测糖尿病人血糖控制的效果，而不能用于糖尿 病的诊断和筛查，也不能作为治疗药物调整的依据。其中型号为"GBZ41-B"的血糖仪具备蓝牙功能，可 将测量结果上传至指定APP，方便用户及时查看个人及家人的健康情况。 ...

乐心医疗(300562.SZ)公告称，公司近日收到广东省药品监督管理局的通知，获悉公司申报的血糖仪医 疗器械注册事宜已通过审批。该产品由主机和配件组成，基于电化学原理，与配套血糖试纸共同使用， 用于家庭患者定量检测指尖新鲜毛细血管全血和医院专业人士定量检测静脉全血中的葡萄糖浓度。其中 型号为"GBZ41-B"的血糖仪具备蓝牙功能，可将测量结果上传至指定APP。该注册证的取得是公司募投 项目"智能血糖监测产品产业化建设项目"建设进程的重要里程碑，有助于增强产品竞争力，进一步拓展 血糖业务。但实际销售情况取决于未来市场推广效果，对公司未来业绩的影响尚无法预测。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The company, 乐心医疗 (Lixun Medical), has received approval from the Guangdong Provincial Drug Administration for its application regarding the registration of blood glucose monitoring medical devices [1] Group 1 - The company has successfully passed the approval process for its blood glucose meter medical device registration [1]

智通财经APP讯，乐心医疗(300562.SZ)公告，公司近日收到广东省药品监督管理局的通知，获悉公司申 报的血糖仪医疗器械注册事宜已通过审批。 ...

乐心医疗 2026 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2026-004 广东乐心医疗电子股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 公司定位于"医疗级远程健康监测设备及服务提供商"，始终高度重视医疗 器械标准符合性，推动全系列产品向医疗级方向发展。上述血糖仪医疗器械注册 证的取得系公司募投项目"智能血糖监测产品产业化建设项目"建设进程的重要 里程碑，有助于公司增强产品竞争力，进一步拓展血糖业务，将对公司战略落地 起到积极作用。未来，公司会积极推动相关产品的销售，为广大股东创造更多价 值。上述产品的实际销售情况取决于未来市场推广效果，公司目前尚无法预测其 乐心医疗 2026 年公告 对公司未来业绩的影响，敬请广大投资者注意投资风险。 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到广东省药品 监督管理局的通知，获悉公司申报的血糖仪医疗器械注册事宜已通过审批，现将 相关内容公告如下： | 产品 | 申请事项 | 注册证编号 | 注册 | 型号、规格 | 结构组成 | | --- | ...

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].